[go: up one dir, main page]

WO1998030223B1 - Traitements lies a la cytokine destines a des affections - Google Patents

Traitements lies a la cytokine destines a des affections

Info

Publication number
WO1998030223B1
WO1998030223B1 PCT/US1998/000634 US9800634W WO9830223B1 WO 1998030223 B1 WO1998030223 B1 WO 1998030223B1 US 9800634 W US9800634 W US 9800634W WO 9830223 B1 WO9830223 B1 WO 9830223B1
Authority
WO
WIPO (PCT)
Prior art keywords
disease
compound
drug
patient
disease comprises
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1998/000634
Other languages
English (en)
Other versions
WO1998030223A1 (fr
Filing date
Publication date
Priority to BR9807473A priority Critical patent/BR9807473A/pt
Priority to SK940-99A priority patent/SK94099A3/sk
Priority to SI9820003A priority patent/SI9820003A/sl
Priority to EP98903474A priority patent/EP0998293A4/fr
Priority to JP53124598A priority patent/JP2002515892A/ja
Priority to CA002278158A priority patent/CA2278158A1/fr
Priority to HU0001526A priority patent/HUP0001526A3/hu
Priority to AU60238/98A priority patent/AU736075B2/en
Priority to IL13049798A priority patent/IL130497A0/xx
Priority to KR1019997006393A priority patent/KR20000070167A/ko
Application filed filed Critical
Publication of WO1998030223A1 publication Critical patent/WO1998030223A1/fr
Publication of WO1998030223B1 publication Critical patent/WO1998030223B1/fr
Priority to NO993439A priority patent/NO993439L/no
Anticipated expiration legal-status Critical
Priority to US09/467,443 priority patent/US6423695B1/en
Priority to NO20004327A priority patent/NO20004327D0/no
Priority to NO20004329A priority patent/NO20004329D0/no
Priority to US10/428,806 priority patent/US20030207826A1/en
Ceased legal-status Critical Current

Links

Abstract

L'invention concerne des nucléosides et d'autres composés permettant de moduler sélectivement des réponses Th1 et Th2 l'une par rapport à l'autre dans le traitement d'affections. Dans un aspect de l'invention, l'administration d'un nucléoside ou d'un autre composé permet de réduire la dose administrée d'un médicament principal. Dans un autre aspect de l'invention, on traite une anomalie révélée par une augmentation de la réponse dans un groupe de cytokines, par administration d'un nucléoside ou d'un autre composé qui augmente la réponse dans un autre groupe de cytokines. Dans un autre aspect de l'invention encore, un patient reçoit un traitement prophylactique consistant en l'administration d'un nucléoside ou d'un autre composé qui réduit sélectivement l'activité Th1, sans réduire de manière significative l'activité Th2. Dans un autre aspect de l'invention enfin, un nucléoside ou un autre composé est administré à un patient à une dose qui diminue le pool d'acide guanosine triphosphorique du patient à un degré réduisant sélectivement l'une des réponses Th1 ou Th2 sans réduction significative de l'autre réponse. Pour obtenir ce résultat, des formes de dosage par libération régulée sont particulièrement intéressantes.
PCT/US1998/000634 1997-01-14 1998-01-13 Traitements lies a la cytokine destines a des affections Ceased WO1998030223A1 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
SK940-99A SK94099A3 (en) 1997-01-17 1998-01-13 Cytokine related treatments of disease
SI9820003A SI9820003A (sl) 1997-01-17 1998-01-13 Zdravljenje bolezni povezano s citokini
EP98903474A EP0998293A4 (fr) 1997-01-17 1998-01-13 Traitements lies a la cytokine destines a des affections
JP53124598A JP2002515892A (ja) 1997-01-17 1998-01-13 サイトカインが関係する疾患治療法
CA002278158A CA2278158A1 (fr) 1997-01-14 1998-01-13 Traitements lies a la cytokine destines a des affections
HU0001526A HUP0001526A3 (en) 1997-01-17 1998-01-13 Use of nucleozides for producing pharmaceutical compositions for cytokine related treatments of disease and the pharmaceutical compositions
AU60238/98A AU736075B2 (en) 1997-01-17 1998-01-13 Cytokine related treatments of disease
KR1019997006393A KR20000070167A (ko) 1997-01-14 1998-01-13 질병의 시토킨 관련 치료 방법
IL13049798A IL130497A0 (en) 1997-01-17 1998-01-13 Controlled release preparations to selectively modulate Th1 and Th2 responses
BR9807473A BR9807473A (pt) 1997-01-17 1998-01-13 Tratamentos de doença relacionados à citocina
NO993439A NO993439L (no) 1997-01-17 1999-07-13 Cytokinrelaterte behandlinger av sykdom
US09/467,443 US6423695B1 (en) 1998-01-13 1999-12-20 Cytokine related treatments of disease
NO20004327A NO20004327D0 (no) 1997-01-17 2000-08-31 Cytokinrelaterte behandlinger av sykdom
NO20004329A NO20004329D0 (no) 1997-01-17 2000-08-31 Cytokinrelaterte behandlinger av sykdom
US10/428,806 US20030207826A1 (en) 1998-01-13 2003-04-30 Cytokine related treatments of disease

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US60/028,586 1996-10-16
US60/036,094 1997-01-14
US3609497P 1997-01-17 1997-01-17
US4397497P 1997-04-23 1997-04-23
US2858697P 1997-04-23 1997-04-23
US60/043,974 1997-04-23
US5548797P 1997-08-12 1997-08-12
US60/055,487 1997-08-12

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1997/018387 Continuation-In-Part WO1998016184A2 (fr) 1996-10-16 1997-10-15 Analogues de nucleosides l purine et leurs utilisations

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US09/467,443 A-371-Of-International US6423695B1 (en) 1998-01-13 1999-12-20 Cytokine related treatments of disease
US09/467,443 Continuation US6423695B1 (en) 1998-01-13 1999-12-20 Cytokine related treatments of disease
US09/594,647 Division US6455690B1 (en) 1996-10-16 2000-06-15 L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
US10/136,745 Division US20020132784A1 (en) 1999-12-20 2002-04-29 Cytokine related treatments of disease

Publications (2)

Publication Number Publication Date
WO1998030223A1 WO1998030223A1 (fr) 1998-07-16
WO1998030223B1 true WO1998030223B1 (fr) 1998-10-01

Family

ID=27487693

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/000634 Ceased WO1998030223A1 (fr) 1997-01-14 1998-01-13 Traitements lies a la cytokine destines a des affections

Country Status (15)

Country Link
EP (1) EP0998293A4 (fr)
JP (3) JP2002515892A (fr)
KR (1) KR20000070167A (fr)
CN (3) CN1253504A (fr)
AU (1) AU736075B2 (fr)
BR (1) BR9807473A (fr)
CA (1) CA2278158A1 (fr)
HU (1) HUP0001526A3 (fr)
IL (1) IL130497A0 (fr)
NO (3) NO993439L (fr)
PL (1) PL336579A1 (fr)
SI (1) SI9820003A (fr)
SK (1) SK94099A3 (fr)
WO (1) WO1998030223A1 (fr)
YU (1) YU61598A (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223743B2 (en) 2000-08-17 2007-05-29 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7226912B2 (en) 2000-08-17 2007-06-05 Tripep Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7261883B2 (en) 2000-08-29 2007-08-28 Tripep Ab Vaccines containing ribavirin and methods of use thereof

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455690B1 (en) * 1996-10-16 2002-09-24 Robert Tam L-8-oxo-7-propyl-7,8-dihydro-(9H)-guanosine
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA007867B1 (ru) 2000-05-26 2007-02-27 Айденикс (Кайман) Лимитед Композиции для лечения флавивирусных и пестивирусных инфекций и способы их применения
KR100801123B1 (ko) 2000-08-17 2008-02-05 트리펩 아베 리바비린 함유 백신 및 이것의 사용 방법
US20050182252A1 (en) 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
ATE423990T1 (de) 2004-05-06 2009-03-15 Us Gov Health & Human Serv Verfahren und zusammensetzungen zur behandlung von uveitis
WO2007104070A1 (fr) * 2006-03-14 2007-09-20 Wholesome Biopharm Pty Ltd Méthode et composition de traitement des maladies allergiques
US8071561B2 (en) 2007-08-16 2011-12-06 Chrontech Pharma Ab Immunogen platform
CN107073002B (zh) * 2014-09-26 2019-10-15 里博科学有限责任公司 作为呼吸道合胞体病毒rna复制抑制剂的4’-乙烯基取代的核苷衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950652A (en) * 1987-03-23 1990-08-21 Hem Research, Inc. dsRNAs for combination therapy in the treatment of viral diseases
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
ES2181673T3 (es) * 1991-05-01 2003-03-01 Jackson H M Found Military Med Procedimiento de tratamiento de las enfermedades respiratorias infecciosas.

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7223743B2 (en) 2000-08-17 2007-05-29 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7226912B2 (en) 2000-08-17 2007-06-05 Tripep Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7241440B2 (en) 2000-08-17 2007-07-10 Tripep Ab Vaccines containing ribavirin and methods of use thereof
US7307066B2 (en) 2000-08-17 2007-12-11 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7439347B2 (en) 2000-08-17 2008-10-21 Tripep Ab Hepatitis C virus non-structural NS3/4A fusion gene
US7638499B2 (en) 2000-08-17 2009-12-29 Tripep Ab Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
US7261883B2 (en) 2000-08-29 2007-08-28 Tripep Ab Vaccines containing ribavirin and methods of use thereof

Similar Documents

Publication Publication Date Title
EP1089726B1 (fr) Composition comprenant de l'acide beta-hydroxy-beta-methylbutyrique et au moins un amino-acide, et methodes d'utilisation correspondantes
US7166640B2 (en) Method of treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract
EP2533785B1 (fr) Traitement de la perte de la sense tu toucher avec des dérivés de la saxitoxine
JP5869469B2 (ja) 鉄が病因に関与する肝臓疾患の処置
JP2004531468A5 (fr)
EP0842660A1 (fr) Composition pour le traitement des condylomes génitaux
EP1369119B1 (fr) Agents de regulation d'expression d'il-12
WO1998030223B1 (fr) Traitements lies a la cytokine destines a des affections
JP2006514092A5 (fr)
WO2021207325A1 (fr) Extraits naturels et leurs composants destinés à être utilisés dans l'atténuation du syndrome de détresse respiratoire aiguë
KR20170128633A (ko) 탈수초성 질환 및 다른 신경계 질환을 앓는 환자에서 신경-인지 및/또는 신경-정신 손상을 개선하기 위한 4-아미노피리딘의 용도
CA2313270A1 (fr) Utilisation de deferiprone pour le traitement et la prevention de maladies cardiaques induites par le fer
Dupuy et al. Intralesional interferon-α and zidovudine in epidemic Kaposi's sarcoma
JP7377717B2 (ja) ２－アミノ－ｌ－（２－（４－フルオロフェニル）－３－（４－フルオロフェニルアミノ）－８，８－ジメチル－５，６－ジヒドロイミダゾ［１，２－ａ］ピラジン－７（８ｈ）－イル）エタノン及びそれらの組み合わせの治療レジメン
US6492339B1 (en) Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
Port et al. Priapism during regular haemodialysis
CA2450915A1 (fr) Utilisation de levosimendane et d'un antagoniste du recepteur beta-adrenergique pour traiter les defaillances cardiaques
CN104758304B (zh) 三七皂苷r1的医药用途
IL106491A0 (en) Anti viral preparations
Dumas et al. Evaluation of trimethoprim and sulphamethoxazole as monotherapy or in combination in the management of toxoplasmosis in murine models
McGREEVY et al. American trypanosomiasis and leishmaniasis
JP2002540150A (ja) ウイルス治療
WO2021202990A2 (fr) Méthodes de traitement d'infections à betacoronavirus
US20230270724A1 (en) PDE3 inhibitors for treating viral infections
RU2000122127A (ru) Цитокин-зависимое лечение заболеваний